Poly Medicure Limited (POLYMED) AI Stock Analysis

• Market Cap: ₹209.77B
• Dividend Yield: 0.14%
• Average Volume (3M): 8.17K
• Price to Earnings (P/E): 58.3
• Beta (1Y): 1.12
• Revenue Growth: 17.26%
• EPS Growth: 26.47%
• Country: IN
• Employees: 6,300
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 9.20
• Shares Outstanding: 101,325,714
• 10 Day Avg. Volume: 9,978
• 30 Day Avg. Volume: 8,170
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹2,154.00
• Price Target Upside: 4.05% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 62 Neutral
• Price Target: ₹2,083.00 ▲(0.62% Upside)

Poly Medicure's strong financial performance is a key strength, supporting a solid score. However, weak technical indicators and high valuation metrics detract from the overall attractiveness of the stock. The absence of earnings call data and corporate events limits further insight.

Poly Medicure Limited Business Overview & Revenue Model

Company Description

Poly Medicure Limited (POLYMED) is a leading Indian medical device company specializing in the manufacturing and distribution of a wide range of healthcare products. The company operates primarily in the medical and healthcare sectors, focusing on developing and supplying high-quality and innovative medical devices and disposables. Its core product offerings include infusion and vascular access devices, anesthesia and respiratory products, surgery and wound drainage products, dialysis and urology products, and blood management devices. POLYMED serves both domestic and international markets, providing critical healthcare solutions to hospitals and healthcare providers worldwide.

How the Company Makes Money

Poly Medicure Limited generates revenue through the sale of its diverse range of medical devices and disposables. The company's primary revenue streams include domestic sales within India and international sales across more than 110 countries. POLYMED's extensive product portfolio caters to various segments of the healthcare industry, including hospitals, clinics, and nursing homes. The company benefits from a robust distribution network and strategic partnerships with healthcare providers and distributors, which enhance its market reach and sales volume. Additionally, POLYMED invests in research and development to innovate and expand its product line, thus driving growth and maintaining a competitive edge in the medical device industry.

Poly Medicure Limited Financial Statement Overview

Summary

Poly Medicure Limited exhibits strong financial health with impressive revenue growth and solid profitability margins. The balance sheet indicates financial stability with low leverage and increasing equity. However, the negative free cash flow highlights the need for careful capital management.

Income Statement

Poly Medicure Limited's income statement reveals impressive revenue growth, with a consistent upward trajectory from 2020 to 2025. The gross profit margin remains strong, reflecting efficient cost management and a solid market position. The net profit margin has also improved, indicating enhanced profitability. However, the EBIT margin shows some fluctuation, suggesting variability in operational efficiency.

Balance Sheet

The balance sheet of Poly Medicure Limited indicates solid financial stability, with a low debt-to-equity ratio that underscores prudent financial management. The company has consistently increased its stockholders' equity, supporting a strong equity ratio. However, despite these strengths, the company's asset base has grown significantly, which could suggest potential capital inefficiencies.

Cash Flow

Poly Medicure Limited's cash flow statements demonstrate a robust operating cash flow, which is a positive indicator of the company's ability to generate cash from its core operations. However, the free cash flow has been negative in recent years due to high capital expenditures, which could pose a risk if not managed carefully. The cash flow from investing activities suggests significant reinvestment into the business, which may drive future growth.

Breakdown	TTM	Dec 2025	Dec 2023	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	16.70B	16.70B	11.15B	13.76B	9.17B	7.75B
Gross Profit	9.26B	11.15B	7.09B	8.89B	4.84B	4.39B
EBITDA	5.03B	4.53B	3.01B	4.19B	2.52B	2.33B
Net Income	3.39B	3.39B	1.79B	2.58B	1.47B	1.36B
Balance Sheet
Total Assets	31.92B	31.92B	15.77B	18.59B	13.77B	12.24B
Cash, Cash Equivalents and Short-Term Investments	12.08B	12.08B	3.09B	2.86B	3.52B	3.74B
Total Debt	1.80B	1.80B	1.49B	1.74B	1.27B	1.37B
Total Liabilities	4.27B	4.27B	3.36B	3.89B	2.89B	2.58B
Stockholders Equity	27.66B	27.66B	12.42B	14.70B	10.87B	9.66B
Cash Flow
Free Cash Flow	0.00	-906.06M	-484.49M	-109.34M	-321.05M	236.01M
Operating Cash Flow	0.00	2.40B	1.91B	2.66B	1.23B	1.19B
Investing Cash Flow	0.00	-11.94B	-1.79B	-2.41B	-853.32M	-4.36B
Financing Cash Flow	0.00	9.51B	-125.05M	-201.53M	-353.38M	3.17B

Poly Medicure Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2070.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:POLYMED, the sentiment is Neutral. The current price of 2070.25 is above the 20-day moving average (MA) of 1956.82, below the 50-day MA of 2082.30, and below the 200-day MA of 2366.88, indicating a neutral trend. The MACD of -37.00 indicates Negative momentum. The RSI at 57.09 is Neutral, neither overbought nor oversold. The STOCH value of 78.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:POLYMED.

Poly Medicure Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERIS	72 Outperform	₹240.94B	62.22		0.42%	30.27%	1.69%
GLAND	68 Neutral	₹322.63B	41.89		0.92%	-2.34%	6.64%
GLAXO	65 Neutral	₹474.25B	49.91		1.93%	6.65%	48.47%
GLENMARK	62 Neutral	₹546.50B	72.52		0.13%	10.99%	―
POLYMED	62 Neutral	₹209.77B	58.27		0.14%	17.26%	26.47%
APLLTD	60 Neutral	₹191.41B	31.74		1.13%	8.20%	-4.26%
Sector *	51 Neutral	$7.89B	-0.12	-39.89%	2.16%	21.38%	-1.56%

Poly Medicure Limited Corporate Events

Poly Medicure Limited Initiates Postal Ballot for Member Approval

Poly Medicure Limited has announced a Postal Ballot Notice seeking approval from its members through a remote e-voting process. This initiative is part of the company’s compliance with SEBI’s Listing Obligations and Disclosure Requirements. The e-voting will be conducted from July 5 to August 3, 2025, with the results to be published on the company’s and stock exchanges’ websites. This move underscores the company’s commitment to transparency and regulatory adherence, potentially impacting its corporate governance and stakeholder relations positively.